Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 112

Results For "health"

4178 News Found

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali
News | May 20, 2025

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds


Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
News | May 18, 2025

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis


Briefs: Dr. Reddy's Laboratories, Relonchem,  Shilpa Pharma Lifesciences and Shanmuga Hospital
News | May 18, 2025

Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA


Shelter Pharma launches three new products
News | May 16, 2025

Shelter Pharma launches three new products

Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India


Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
News | May 16, 2025

Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025


Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'
News | May 14, 2025

Emcutix launches urea-based skin-care moisturizers ‘Ureaderm'

Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration


Bayer confirms 2025 targets after solid start to the year
News | May 14, 2025

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)


Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
News | May 14, 2025

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore


Briefs: Zydus and CuraTeQ Biologics
Drug Approval | May 14, 2025

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA